#	Pagina
attuale pagina	/open-h2020/projects/212475/index.html

Opendata, web and dolomites

NEOSETAC SIGNED

New Selenium-based Targeted Nanocapsules to treat Breast Cancer

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

NEOSETAC project word cloud

Explore the words cloud of the NEOSETAC project. It provides you a very rough idea of what is the project "NEOSETAC" about.

prevent seleniumbased limited million therapy pharmacokinetic 13 se window successful efficacy incidences chronic advantages cancers cancer half drug neosetac selenium causing systemic chemotherapy clinical therapeutic accounting treatment nps metastasis 4 anti complexity desired ing big life women enhanced amount twice breast compounds nanoparticles annually tumor communicable time toxicity place biodegradable release location diseases hours cell narrow ligands worldwide stem dietary deaths chemoprevention functionalize until world anticancer loading 18 recurrence 411 093 relatively activation lesions supplement alliance

Project "NEOSETAC" data sheet

The following table provides information about the project.

Coordinator	UNIVERSIDAD AUTONOMA DE BARCELONA Organization address address: CALLE CAMPUS UNIVERSITARIO SN CERDANYOLA V city: CERDANYOLA DEL VALLES postcode: 8290 website: http://www.uab.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	504˙000 €
EC max contribution	504˙000 € (100%)
Programme	1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
Code Call	H2020-MSCA-RISE-2017
Funding Scheme	MSCA-RISE
Starting year	2018
Duration (year-month-day)	from 2018-01-01 to 2021-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	UNIVERSIDAD AUTONOMA DE BARCELONA UNIVERSIDAD AUTONOMA DE BARCELONA Organization address address: CALLE CAMPUS UNIVERSITARIO SN CERDANYOLA V city: CERDANYOLA DEL VALLES postcode: 8290 website: http://www.uab.es contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (CERDANYOLA DEL VALLES)	coordinator	171˙000.00
2	KAROLINSKA INSTITUTET KAROLINSKA INSTITUTET Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 website: www.ki.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (STOCKHOLM)	participant	171˙000.00
3	ACIB GMBH ACIB GMBH Organization address address: KRENNGASSE 37/2 city: GRAZ postcode: 8010 website: www.acib.at contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (GRAZ)	participant	54˙000.00
4	AB BCN S.L. AB BCN S.L. Organization address address: LG BELLATERRA PARC DE RECERCA city: CERDANYOLA DEL VALLES postcode: 8193 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (CERDANYOLA DEL VALLES)	participant	45˙000.00
5	ADSI-AUSTRIAN DRUG SCREENING INSTITUTE GMBH ADSI-AUSTRIAN DRUG SCREENING INSTITUTE GMBH Organization address address: INNRAIN 66A city: INNSBRUCK postcode: 6020 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (INNSBRUCK)	participant	36˙000.00
6	REGION STOCKHOLM REGION STOCKHOLM Organization address address: HANTVERKARGATAN 45 city: STOCKHOLM postcode: 104 22 website: www.sll.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (STOCKHOLM)	participant	27˙000.00
7	QUALIZYME DIAGNOSTICS GMBH & CO KG QUALIZYME DIAGNOSTICS GMBH & CO KG Organization address address: NEUE STIFTINGTALSTRASSE 2 city: GRAZ postcode: 8010 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AT (GRAZ)	participant	0.00

Map

Project objective

The European Chronic Diseases Alliance has defined cancer as one of the major non-communicable diseases, accounting for 13% of the deaths worldwide, resulting in 8.2 million deaths annually. In the NEOSETAC project, breast cancer will be the focus of study being the most common cancers in women. It comprises of 10.4% of all the cancer incidences among women, causing 411 093 deaths per year overall the world. In Europe, there is more than twice of the amount of new breast cancer cases annually than new cases of cancer in any other place. The complexity of breast cancer makes it a big challenge for successful treatment. The NEOSETAC project will demonstrate the anti-cancer therapeutic potential of a novel Seleniumbased therapy for the management of breast cancer. The clinical application of Selenium (Se) compounds for cancer treatment is until now limited in chemoprevention as dietary supplement. In this proposal, we aim to improve the therapeutic window, pharmacokinetic properties and targeting drug delivery via nanoparticles (NPs). By loading Se into biodegradable NPs, drug release is controlled within the narrow therapeutic window of Se. At the same time the uptake and activation of Se compounds at desired location (tumor lesions and metastasis) is achieved. We also propose to functionalize NPs by cancer cell / cancer stem cell targeting ligands to further improve the therapeutic efficacy and prevent cancer recurrence after chemotherapy. These advantages will lead to an enhanced anticancer activity and reduced systemic toxicity. Moreover, targeting via NPs will improve the pharmacokinetic properties and increase the relatively short half-life (~18 hours) of Se.

Deliverables

List of deliverables.
Dissemination and Communication Strategy defined including promotional kit	Documents, reports	2020-03-18 18:53:26
Report of in vitro tests results and Se speciation of targeted nanosystems	Documents, reports	2020-03-11 14:42:15

Take a look to the deliverables list in detail: detailed list of NEOSETAC deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2019	Viktorija Vidimce-Risteski Flash Talk: [NEOSETAC]New Selenium-based Targeted Nanocapsules to treat Breast Cancer published pages: , ISSN: , DOI:	European Summit of Industrial Biotechnology	2020-03-18
2018	MarÃa-JesÃºs SÃ¡nchez-MartÃn, Ying Zhao, Wenyi Zheng, Moustapha Hassan and Manuel Valiente NEW SELENIUM-BASED NANOCAPSULES TO TREAT BREAST CANCER: NEOSETAC BACKGROUND published pages: , ISSN: , DOI:	ONCO EMERGENCE FORUM BARCELONA 2018	2020-03-18
2019	Wenyi Zheng, Roberto Boada, Rui He, Tingting Xiao, Fei Ye, Laura Simonelli, Manuel Valiente, Ying Zhao, Moustapha Hassan Extracellular Albumin Covalently Sequesters Selenocompounds and Determines Cytotoxicity published pages: 4734, ISSN: 1422-0067, DOI: 10.3390/ijms20194734	International Journal of Molecular Sciences 20/19	2020-03-18
2019	Viktorija Vidimce-Risteski, Meritxell Galindo Casas, Wenyi Zheng, Claudia Tallian-Langer, Laura TeixidÃ³ Devesa, Iris H.Valido, Jorge RodrÃguez-MartÃnez, Sandra Diez-GarcÃa, Rui He, Lorena Sansegundo Barbosa, Simone Weinberger, Neus Sanchez Alberola,Ying Zhao, Maria-JesÃºs Sanchez-Martin, Doris Ribitsch, Michaela PreÃŸnig, Moustapha Hassan and Manuel Valiente Poster: NEOSETAC [ New Selenium-based Targeted Nanocapsules to treat Breast Cancer ] published pages: , ISSN: , DOI:	European Summit of Industrial Biotechnology	2020-03-18

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEOSETAC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NEOSETAC" are provided by the European Opendata Portal: CORDIS opendata.